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Substantial  evidence exists 
that non-CNS infection can cause 
neuropsychiatric presentations in 
the absence of delirium,4 which 
has now been shown with severe 
acute respiratory syndrome corona-
virus 2 infection.5 We therefore 
strongly disagree that all acute 
COVID-associated neuropsychiatric 
phenomenology can be explained 
by delirium. Full detailed analysis of 
stage 2 and 3 data from this study is 
underway and the multidisciplinary 
authors will continue to be guided by 
the clinical data and underlying disease 
mechanisms. 
Altered mental status will continue 
to remain an important term in our 
global WHO and World Federation of 
Neurology studies of COVID-19 and 
the brain until these mechanisms 
are elucidated. We welcome ongoing 
discussions and collaborations on 
the intersections of these complex 
concepts and disorders as this 
important work progresses.
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Authors’ reply
We thank Dorothy Wade and 
colleagues and Mark Oldham and 
colleagues for their recognition 
of the cross-speciality effort 
of members of the UK’s major 
professional neuroscience bodies 
who undertook this challenging UK-
wide study during the exponential 
phase of the COVID-19 pandemic.1 
We also welcome the involvement 
of geriatricians and psychologists in 
future research. 
We agree that delirium is common, 
especially in severe infections and in 
the intensive care unit. As stated in 
our Article, we acknowledge that the 
study might have under-ascertained 
[A: Could we rephrase to “not have 
recorded all such cases” or similar?] 
such cases. Changes in mental 
status with clear and recognised 
risk factors were not the focus of 
this study (eg, those explained 
by severe systemic illness and 
associated with dementia or cognitive 
impairment). We agree that if such 
commonly observed complications 
were included, they might have 
substantially increased the numbers 
[A: Please be more specific – the 
number of patients with delirium?], 
mirroring the situation in other 
critical illnesses. In this situation, the 
burden of CNS complications arising 
from COVID-19 would be even greater 
than we found in our study.
We agree that consistent termi-
nology is needed for the many 
causes of alterations of mental state 
and an improved understanding 
of the underlying pathophysiology 
that should determine this is 
urgently required. We acknowledge 
the position paper on a proposed 
terminology of these complex 
presentations and, appreciating the 
value of multidisciplinary approaches, 
would support involvement of the 
professional bodies in relevant areas 
of psychiatry, neuropsychiatry, and 
neurological infection, as well as 
patient and public involvement, in 
future iterations. 
We understand the motivations 
for wishing to avoid the term altered 
mental status. However, we carefully 
considered the information notified 
and took an ontological approach 
for over-arching terms that include 
disturbances of mental state occurring 
without the clinical features of 
delirium (including isolated psychosis, 
catatonia, anxiety, and mania). 
Our study was done with clear 
a-priori clinical case definitions, 
such as encephalitis, to support the 
experienced clinicians reporting cases, 
reflecting national guidelines, and it 
was clearly intended to report acute 
presentations. We took a strong view 
that the knowledge of the bedside 
specialist clinician assessing the 
patient was inherently valuable, and 
that rediagnosing patients from a 
distance would be neither wise nor 
accurate. Psychiatrists, for example, 
commonly differentiate psychosis 
from psychotic symptoms occurring 
as part of delirium; indeed, it is routine 
practice to provide reassurance that 
new-onset psychosis is actually 
delirium and should resolve. Even 
in 1918, both psychiatrists and 
neurologists, including Menninger 
and von Economo,3 were careful to 
distinguish patients with primary brain 
dysfunction or disease from those 
whose symptoms were explained by 
systemic processes [A: Edit OK?].
Our study was designed from the 
outset in a three-stage approach: 
stage 1 is the core dataset provided 
by clinicians during the pandemic;1 
stage 2 is detailed clinical data 
collection; and stage 3 is to evaluate 
disease mechanisms, including viral 
neurotropism and para-infectious or 
post-infectious innate and adaptive 
immune responses, polygenic 
risk, endothelial dysfunction, and 
coagulopathy. Stages 2 and 3 are 
underway.
[A: We have edited your letter to avoid 
repetition, enhance readability, reduce length, 
and achieve consistency with Lancet style.]
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